1 line
27 KiB
Plaintext
1 line
27 KiB
Plaintext
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,8]],"date-time":"2023-12-08T16:04:46Z","timestamp":1702051486186},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T00:00:00Z","timestamp":1664841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zusammen gegen den Krebs e.V."},{"name":"University Leipzig"},{"name":"DGIM"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>For most acute myeloid leukemia (AML) patients an allogeneic hematopoietic stem cell transplantation (HSCT) offers the highest chance of cure. The introduction of less toxic non-myeloablative conditioning (NMA) regimes enabled older and\/or comorbid patients to be consolidated with an allogeneic HSCT. While the hematopoietic cell transplantation comorbidity index (HCT-CI) predicted outcomes in many younger patient cohorts its impact in older AML patients receiving NMA-HSCT remains unknown. Here we analyzed 289 AML patients 60 years or older\u00a0(median age 66, range 60-77 years) undergoing NMA-HSCT (2 or 3 Gray total body irradiation and 3 days of fludarabine 30\u2009mg\/m<jats:sup>2<\/jats:sup>). HCT-CI risk was low, intermediate, or high in 36%, 31%, and 33% of patients, respectively. Non-relapse mortality (NRM), cumulative incidence of relapse (CIR), and overall survival (OS) did not differ between HCT-CI groups. The HCT-CI also did not impact outcomes when considering the European LeukemiaNet 2017 risk at diagnosis or the measurable residual disease (MRD) status at HSCT. Notably, MRD-negative older NMA-transplanted AML patients had a beneficial OS of 49% after 5 years. Since a higher HCT-CI did not impair outcomes, age or comorbidities per se should not impede NMA-HSCT, presenting a feasible consolidation option for this group of AML patients.<\/jats:p>","DOI":"10.1038\/s41409-022-01833-0","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T12:02:54Z","timestamp":1664884974000},"page":"30-38","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years or older"],"prefix":"10.1038","volume":"58","author":[{"given":"Donata","family":"Backhaus","sequence":"first","affiliation":[]},{"given":"Dominic","family":"Brauer","sequence":"additional","affiliation":[]},{"given":"Rosmarie","family":"Pointner","sequence":"additional","affiliation":[]},{"given":"Lara","family":"Bischof","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-8398-285X","authenticated-orcid":false,"given":"Vladan","family":"Vucinic","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0001-8239-002X","authenticated-orcid":false,"given":"Georg-Nikolaus","family":"Franke","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-4737-1103","authenticated-orcid":false,"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-2270-0804","authenticated-orcid":false,"given":"Madlen","family":"Jentzsch","sequence":"additional","affiliation":[]},{"ORCID":"http:\/\/orcid.org\/0000-0002-1315-2332","authenticated-orcid":false,"given":"Sebastian","family":"Schwind","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,10,4]]},"reference":[{"key":"1833_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347.","journal-title":"Blood"},{"key":"1833_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405.","journal-title":"Blood"},{"key":"1833_CR3","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2019001239","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Wei AH. How I treat acute myeloid leukemia in the era of new drugs. Blood. 2020;135:85\u201396.","journal-title":"Blood"},{"key":"1833_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"key":"1833_CR5","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, et al. Age and acute myeloid leukemia: Real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179\u201387.","journal-title":"Blood"},{"key":"1833_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/j.1445-5994.1999.tb00711.x","volume":"29","author":"A Grigg","year":"1999","unstructured":"Grigg A, Seymour JF, Roberts A, Szer J. Mini-allografts\u2019 for haematological malignancies: an alternative to conventional myeloablative marrow transplantation. Aust N. Z J Med. 1999;29:308\u201314.","journal-title":"Aust N. Z J Med"},{"key":"1833_CR7","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1182\/blood-2002-05-1340","volume":"101","author":"D Niederwieser","year":"2003","unstructured":"Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood. 2003;101:1620\u20139.","journal-title":"Blood"},{"key":"1833_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KE, MacKenzie CR. A New Method of Classifying Prognostic Comorbidity in Longitudinal Studies: Development and Validation. J Chronic Dis. 1987;40:373\u201383.","journal-title":"J Chronic Dis"},{"key":"1833_CR9","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","volume":"106","author":"ML Sorror","year":"2005","unstructured":"Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)\u2013 specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912\u20139.","journal-title":"Blood"},{"key":"1833_CR10","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.bbmt.2008.11.023","volume":"15","author":"SM Pollack","year":"2009","unstructured":"Pollack SM, Steinberg SM, Odom J, Dean RM, Fowler DH, Bishop MR. Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non-Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2009;15:223\u201330.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1833_CR11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.bbmt.2005.05.008","volume":"11","author":"DMB Kerbauy","year":"2005","unstructured":"Kerbauy DMB, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM, et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transpl. 2005;11:713\u201320.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1833_CR12","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/bmt.2009.236","volume":"45","author":"ZY Lim","year":"2010","unstructured":"Lim ZY, Ingram W, Brand R, Ho A, Kenyon M, Devereux S, et al. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transpl. 2010;45:633\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"1833_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/leu.2009.1","volume":"23","author":"L Farina","year":"2009","unstructured":"Farina L, Bruno B, Patriarca F, Spina F, Sorasio R, Morelli M, et al. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. Leukemia. 2009;23:1131\u20138.","journal-title":"Leukemia"},{"key":"1833_CR14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.bbmt.2016.10.017","volume":"23","author":"P Barba","year":"2017","unstructured":"Barba P, Ratan R, Cho C, Ceberio I, Hilden P, Devlin SM, et al. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transpl. 2017;23:67\u201374.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1833_CR15","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1016\/j.bbmt.2011.06.009","volume":"17","author":"N Birninger","year":"2011","unstructured":"Birninger N, Bornh\u00e4user M, Schaich M, Ehninger G, Schetelig J. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation-investigation of potential limitations of the index. Biol Blood Marrow Transpl. 2011;17:1822\u201332.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1833_CR16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.bbmt.2014.06.005","volume":"20","author":"A Nakaya","year":"2014","unstructured":"Nakaya A, Mori T, Tanaka M, Tomita N, Nakaseko C, Yano S, et al. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A Prospective multicenter validation study of the kanto study group for cell therapy. Biol Blood Marrow Transpl. 2014;20:1553\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1833_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/bmt.2008.300","volume":"43","author":"R Guilfoyle","year":"2009","unstructured":"Guilfoyle R, Demers A, Bredeson C, Richardson E, Rubinger M, Szwajcer D, et al. Performance status, but not the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI), predicts mortality at a Canadian transplant center. Bone Marrow Transpl. 2009;43:133\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"1833_CR18","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41409-020-01032-9","volume":"56","author":"M Yanada","year":"2021","unstructured":"Yanada M, Konuma T, Mizuno S, Saburi M, Shinohara A. Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. Bone Marrow Transpl. 2021;56:387\u201394.","journal-title":"Bone Marrow Transpl"},{"key":"1833_CR19","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/bmt.2011.138","volume":"47","author":"SW Bokhari","year":"2012","unstructured":"Bokhari SW, Watson L, Nagra S, Cook M, Byrne JL, Craddock C, et al. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoietic progenitor cell transplantation. Bone Marrow Transpl. 2012;47:528\u201334.","journal-title":"Bone Marrow Transpl"},{"key":"1833_CR20","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/bmt.2015.165","volume":"50","author":"FV Michelis","year":"2015","unstructured":"Michelis FV, Messner HA, Atenafu EG, McGillis L, Lambie A, Uhm J, et al. Patient age, remission status and HCT-CI in a combined score are prognostic for patients with AML undergoing allogeneic hematopoietic cell transplantation in CR1 and CR2. Bone Marrow Transpl. 2015;50:1405\u201310.","journal-title":"Bone Marrow Transpl"},{"key":"1833_CR21","doi-asserted-by":"publisher","first-page":"3864","DOI":"10.1182\/bloodadvances.2020001904","volume":"4","author":"J Grimm","year":"2020","unstructured":"Grimm J, Jentzsch M, Bill M, Goldmann K, Schulz J, Niederwieser D, et al. Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation. Blood Adv. 2020;4:3864\u201374.","journal-title":"Blood Adv"},{"key":"1833_CR22","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00277-018-3373-y","volume":"97","author":"M Bill","year":"2018","unstructured":"Bill M, Grimm J, Jentzsch M, Kloss L, Goldmann K, Schulz J, et al. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients. Ann Hematol. 2018;97:1757\u201365.","journal-title":"Ann Hematol"},{"key":"1833_CR23","doi-asserted-by":"crossref","unstructured":"Jentzsch M, Bill M, Grimm J, Schulz J, Goldmann K, Beinicke S, et al. High BAALC copy numbers in peripheral blood prior to allogeneic transplantation predict early relapse in acute myeloid leukemia patients. Oncotarget. 2017;8:87944\u201354.","DOI":"10.18632\/oncotarget.21322"},{"key":"1833_CR24","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1097\/HS9.0000000000000167","volume":"3","author":"M Jentzsch","year":"2019","unstructured":"Jentzsch M, Bill M, Grimm J, Schulz J, Beinicke S, H\u00e4ntschel J, et al. Prognostic Impact of Blood MN1 Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid. Leuk Hemasphere. 2019;3:e167.","journal-title":"Leuk Hemasphere"},{"key":"1833_CR25","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/leu.2010.283","volume":"25","author":"T Lange","year":"2011","unstructured":"Lange T, Hubmann M, Burkhardt R, Franke GN, Cross M, Scholz M, et al. Monitoring of WT1 expression in PB and CD34 donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning. Leukemia. 2011;25:498\u2013505.","journal-title":"Leukemia"},{"key":"1833_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00471-x","volume":"11","author":"M Jentzsch","year":"2021","unstructured":"Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Schulz J, et al. Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation. Blood Cancer J. 2021;11:80.","journal-title":"Blood Cancer J"},{"key":"1833_CR27","unstructured":"National Marrow Donor Program and The Medical College of Wisconsin. Appendix M\u2014The Hematopoietic Cell Transplant-Co-morbidity Index (HCT-CI). https:\/\/www.cibmtr.org\/DataManagement\/TrainingReference\/Manuals\/DataManagement\/Documents\/appendix-m.pdf, 2012."},{"key":"1833_CR28","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","volume":"121","author":"ML Sorror","year":"2013","unstructured":"Sorror ML. How I assess comorbidities before hematopoietic cell transplantation. Blood. 2013;121:2854\u201363.","journal-title":"Blood"},{"key":"1833_CR29","unstructured":"R Development Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing (2017). http:\/\/www.R-project.org. Accessed 15 April 2022."},{"key":"1833_CR30","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc. 1958;53:457\u201381.","journal-title":"J Am Stat Assoc"},{"key":"1833_CR31","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ. Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat. 1988;16:1141\u201354.","journal-title":"Ann Stat"},{"key":"1833_CR32","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1182\/blood-2017-03-772368","volume":"130","author":"L Muffly","year":"2017","unstructured":"Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017;130:1156\u201364.","journal-title":"Blood"},{"key":"1833_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4084\/mjhid.2020.081","volume":"12","author":"G Magliano","year":"2020","unstructured":"Magliano G, Bacigalupo A. Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia of the elderly: Review of literature and new perspectives. Mediterr J Hematol Infect Dis. 2020;12:1\u20138.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"1833_CR34","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.bbmt.2006.06.003","volume":"12","author":"EP Alyea","year":"2006","unstructured":"Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R, et al. Impact of Conditioning Regimen Intensity on Outcome of Allogeneic Hematopoietic Cell Transplantation for Advanced Acute Myelogenous Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transpl. 2006;12:1047\u201355.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1833_CR35","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.bbmt.2017.06.005","volume":"23","author":"M Veeraputhiran","year":"2017","unstructured":"Veeraputhiran M, Yang L, Sundaram V, Arai S, Lowsky R, Miklos D, et al. Validation of the Hematopoietic Cell Transplantation\u2013Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2017;23:1744\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1833_CR36","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/leu.2014.164","volume":"29","author":"J Versluis","year":"2015","unstructured":"Versluis J, Labopin M, Niederwieser D, Socie G, Schlenk RF, Milpied N, et al. Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Leukemia. 2015;29:51\u201357.","journal-title":"Leukemia"},{"key":"1833_CR37","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.bbmt.2009.11.008","volume":"16","author":"P Barba","year":"2010","unstructured":"Barba P, Pi\u00f1ana LJ, Martino R, Valc\u00e1rcel D, Amor\u00f3s A, Sureda A, et al. Comparison of Two Pretransplant Predictive Models and a Flexible HCT-CI Using Different Cut off Points to Determine Low-, Intermediate-, and High-Risk Groups: The Flexible HCT-CI Is the Best Predictor of NRM and OS in a Population of Patients Undergoing allo-RIC. Biol Blood Marrow Transpl. 2010;16:413\u201320.","journal-title":"Biol Blood Marrow Transpl"},{"key":"1833_CR38","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1200\/JCO.2009.25.4821","volume":"28","author":"BL McClune","year":"2010","unstructured":"McClune BL, Weisdorf DJ, Pedersen TL, Tunes da Silva G, Tallman MS, Sierra J, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010;28:1878\u201387.","journal-title":"J Clin Oncol"},{"key":"1833_CR39","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1001\/jama.2011.1558","volume":"306","author":"ML Sorror","year":"2011","unstructured":"Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, et al. Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning. JAMA. 2011;306:1874\u201383.","journal-title":"JAMA"},{"key":"1833_CR40","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1038\/bmt.2010.227","volume":"46","author":"L Castagna","year":"2011","unstructured":"Castagna L, F\u00fcrst S, Marchetti N, El Cheikh J, Faucher C, Mohty M. Retrospective analysis of common scoring systems and outcome in patients older than 60 years treated with reduced-intensity conditioning regimen and alloSCT. Bone Marrow Transpl. 2011;46:1000\u20135.","journal-title":"Bone Marrow Transpl"},{"key":"1833_CR41","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/leu.2008.197","volume":"22","author":"A Xhaard","year":"2008","unstructured":"Xhaard A, Porcher R, Chien JW, de Latour RP, Robin M, Ribaud P, et al. Impact of comorbidity indexes on non-relapse mortality. Leukemia. 2008;22:2062\u20139.","journal-title":"Leukemia"},{"key":"1833_CR42","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3324\/haematol.2014.103655","volume":"99","author":"LS Muffly","year":"2014","unstructured":"Muffly LS, Kocherginsky M, Stock W, Chu Q, Bishop MR, Godley LA, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014;99:1373\u20139.","journal-title":"Haematologica"},{"key":"1833_CR43","doi-asserted-by":"publisher","first-page":"5584","DOI":"10.1182\/bloodadvances.2021005974","volume":"5","author":"V Vucinic","year":"2021","unstructured":"Vucinic V, Ruhnke L, Sockel K, R\u00f6hnert MA, Backhaus D, Brauer D, et al. The Diagnostic Red Blood Cell Distribution Width as a Prognostic Factor in Acute Myeloid Leukemia. Blood Adv. 2021;5:5584\u20137.","journal-title":"Blood Adv"},{"key":"1833_CR44","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1097\/HS9.0000000000000532","volume":"5","author":"D Brauer","year":"2021","unstructured":"Brauer D, Backhaus D, Pointner R, Vucinic V, Niederwieser D, Platzbecker U, et al. Nutritional Status at Diagnosis and Pre-transplant Weight Loss Impact Outcomes of Acute Myeloid Leukemia Patients following Allogeneic Stem Cell Transplantation. Hemasphere. 2021;5:e532.","journal-title":"Hemasphere"},{"key":"1833_CR45","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s12185-017-2183-7","volume":"105","author":"T Ando","year":"2017","unstructured":"Ando T, Yamazaki E, Ogusa E, Ishii Y, Yamamoto W, Motohashi K, et al. Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. Int J Hematol. 2017;105:623\u201330.","journal-title":"Int J Hematol"},{"key":"1833_CR46","doi-asserted-by":"publisher","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","volume":"6","author":"BM Sandmaier","year":"2019","unstructured":"Sandmaier BM, Kornblit B, Storer BE, Olesen G, Maris MB, Langston AA, et al. Addition of sirolimus to cyclosporine and mycophenolate mofetil-based graft-versus-host disease prophylaxis after unrelated nonmyeloablative hematopoietic cell transplantation: A multicentre phase III randomized trial. Lancet Haematol. 2019;6:e409\u2013e418.","journal-title":"Lancet Haematol"},{"key":"1833_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0114735","volume":"9","author":"PD Ziakas","year":"2014","unstructured":"Ziakas PD, Zervou FN, Zacharioudakis IM, Mylonakis E. Graft-versus-host disease prophylaxis after transplantation: A network meta-analysis. PLoS One. 2014;9:1\u201318.","journal-title":"PLoS One"},{"key":"1833_CR48","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation. N. Eng J Med. 2017;377:2433\u201344.","journal-title":"N. Eng J Med"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01833-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01833-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01833-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T09:03:39Z","timestamp":1672823019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-022-01833-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,4]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1833"],"URL":"http:\/\/dx.doi.org\/10.1038\/s41409-022-01833-0","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":["Transplantation","Hematology"],"published":{"date-parts":[[2022,10,4]]},"assertion":[{"value":"12 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}} |